Indian Oil Corporation Ltd. makes a corporate announcement

No. On the latest disclosed facts, IOC should not be treated as compliant with SEBI (LODR)’s independent-director requirement. The company had already reported a shortfall in the requisite number of independent directors, including a woman independent director, for the quarter ended June 30, 2026 ^[1]. Dr. Alka Mundra then ceased to be an independent director effective September 18, 2026 ^[2]. No subsequent replacement is disclosed in the cited filings.

Under Regulation 17(1E) of the SEBI (LODR) Regulations, a vacancy in the office of an independent director must be filled at the earliest and within three months from the date of the vacancy. Accordingly, for a vacancy arising on September 18, 2026, the statutory deadline is December 18, 2026.

The deadline to fill Mundra’s seat does not necessarily cure the broader compliance issue: IOC had indicated that the board’s shortfall involved both the number of independent directors and the woman-independent-director requirement, with appointments controlled by the Ministry of Petroleum and Natural Gas ^[1]. Therefore, IOC may need more than one appointment to restore full board and committee compliance.

Dr. Alka Mundra was not a member of either the Audit Committee or the Nomination & Remuneration Committee. IOC’s resignation disclosure expressly states that she was not a member of any Board committee. ^[2]

Therefore, her departure does not itself create a committee vacancy or require immediate reconstitution of either committee to replace her. The relevant issue predates her resignation:

• IOC had discontinued the Audit Committee and Nomination & Remuneration Committee from 28 March 2026 because there were no Independent Directors on the Board. ^[3]
• The committees had not been reconstituted as of the annual-report reporting date. ^[4]
• The Nomination & Remuneration Committee requires at least two-thirds of its directors to be Independent Directors; the Audit Committee must be constituted as a qualified and independent committee. ^[5]
• IOC’s stated position was that the committees would be reconstituted when the Government of India appointed the requisite Independent Directors. ^[3]

Implication: Mundra’s resignation removes one Independent Director from the Board, but not from either committee. It does not trigger an immediate committee reconstitution caused by loss of her seat. However, the underlying requirement to restore compliant Audit and Nomination & Remuneration Committees remains unresolved and depends on IOC having enough serving Independent Directors; her departure makes that remediation more difficult, not redundant. The cited filings do not establish a separate, resignation-specific statutory deadline for immediate reconstitution.

Verdict: IOC and BPCL currently show the same fundamental governance weakness: the latest evidenced board position is zero sitting independent directors, with both companies having experienced 100% turnover of their relevant FY26 independent-director cohorts. IOC’s record is particularly weak on vacancy management: successive gaps in required independent-director strength have extended beyond the commonly applied three-month appointment benchmark, and the latest three-director vacancy remained unfilled for roughly four and a half months before a new appointment was made.

Current comparison

IOC’s most recent appointment also demonstrates unusually short effective tenure: Dr Mundra served for approximately five weeks before resigning over an independence concern related to her son’s IndianOil retail-outlet dealership. ^{[15] [2]} This is not comparable to BPCL’s tenure-driven departures, but it materially worsened IOC’s current board-independence position.

IOC’s vacancy-filling record

Using the three-month benchmark for filling an independent-director vacancy:

• FY23–FY24: IOC reported that it lacked a woman independent director throughout the year and did not maintain at least 50% independent directors during 1 April–2 May 2023 and 16 January–31 March 2024. ^[16] These were not isolated end-period issues; they indicate recurring difficulty in maintaining the required composition.
• November 2024–March 2025: Three IOC independent directors’ earlier three-year terms ended on 23 November 2024. ^[17] They were reappointed only with effect from 28 March 2025. ^[18] The resulting gap was approximately four months, placing the reappointments beyond a three-month benchmark.
• April 2025: Dr Ram Naresh Singh ceased to be an independent director on 8 April 2025 after completing his three-year term. ^[10] The record does not show a replacement within three months.
• March–August 2026: The three reappointed directors ceased on 28 March 2026, leaving IOC with no independent directors and forcing the discontinuation of key statutory committees for the remainder of FY26. ^{[19] [20]} The next independent-director appointment evidenced was Dr Mundra’s appointment effective 15 August 2026. ^[7] That is approximately four and a half months after the March vacancy, again outside the three-month benchmark.
• September 2026: Mundra’s resignation on 18 September 2026 returned the board to a zero-independent-director position. ^[2]

Analyst read: IOC’s historical record is not one of timely vacancy replacement. It shows repeated composition shortfalls, delayed reappointments and, most seriously, a period in which the Audit Committee, Nomination and Remuneration Committee, Stakeholders’ Relationship Committee and Risk Management Committee could not operate because no independent director was available. ^[19] The company attributes the delays to the fact that appointments are controlled by the Ministry of Petroleum and Natural Gas rather than by the company itself. ^[19] That explains the execution constraint, but it does not remove the regulatory or governance consequence.

BPCL’s experience is not materially better: it reported a shortage of one independent director since May 2023 and also had no independent directors after 28 March 2026. ^[11] Thus, IOC appears broadly aligned with BPCL on structural appointment risk; a definitive comparison with HPCL remains unconfirmed.